SCHEMBL163727

SCHEMBL163727

CNS(=O)(=O)c1ccc(CC(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.59
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 2/20 0.55
TBXA2R P21731 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 2/20 0.52
CA2 P00918 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA3 P07451 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA13 Q8N1Q1 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
CASP6 P55212 1/20 0.49
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396644 0.85 SMN1; SMN2 (0.52) MEP1BALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL16880041 0.84 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2GAACA2CA12
SCHEMBL395695 0.83 SMN1; SMN2 (0.46) MEP1BALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL24032613 0.82 SMN1; SMN2 (0.59) ALDH1A1KDM4ESMN1; SMN2GAACA2
SCHEMBL166809 0.82 ALDH1A1 (0.71) MEP1BALDH1A1KDM4ETBXA2RLMNA
SCHEMBL5489381 0.82 ALDH1A1 (0.71) ALDH1A1GAACA2CA1LMNA
SCHEMBL5450110 0.81 NPSR1 (0.72) MEP1BALDH1A1KDM4ETBXA2RGAA
SCHEMBL2519032 0.81 MEP1B (0.55) MEP1BALDH1A1KDM4ETBXA2RSMN1; SMN2
SCHEMBL5447486 0.80 TBXA2R (0.65) MEP1BALDH1A1KDM4ETBXA2RGAA
SCHEMBL3846633 0.80 PTGDR2 (0.49) LMNAEGFRERBB2AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317686-A1 RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2024-09-26 US disclosed
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 CN disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
CN-111315735-B Dihydrobenzimidazolone C4医药公司 2024-03-08 CN disclosed
EP-4273129-A1 RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273129-A1 RORgammaT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-11-08 EP disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 US disclosed
WO-2022143771-A1 RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-07-07 WO disclosed
WO-2022143771-A1 RORγT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-07-07 WO disclosed
WO-2015101928-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-09 WO disclosed
WO-2015101928-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-09 WO disclosed
WO-2013171729-A2 ARYL AND HETEROARYL AMIDE COMPOUNDS AS RORGAMAT MODULATOR GLENMARK PHARMACEUTICALS S.A. (CH) 2013-11-21 WO disclosed
US-8410094-B2 Amide compounds, their pharmaceutical compositions, their preparation method and their uses SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-04-02 US disclosed
WO-2012028100-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed
WO-2012028100-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed
US-20110251192-A1 AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR PREPARATION METHOD AND THEIR USES SHANGHAI TARGETDRUG CO., LTD. (CN) 2011-10-13 US disclosed
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed
EP-1451172-A1 THERAPEUTIC ISOQUINOLINE COMPOUNDS AstraZeneca AB (SE) 2004-09-01 EP disclosed
WO-2003037887-A1 THERAPEUTIC ISOQUINOLINE COMPOUNDS ASTRAZENECA AB (SE) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010526-A1 Therapeutic isoquinoline compounds HTR1B, HTR1D, HTR1A MEP1B 1965/4885ALDH1A1 816/4885KDM4E 1824/4885
US-20240317686-A1 RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF RORC, RORB, RORA MEP1B 2262/4885ALDH1A1 1160/4885KDM4E 2668/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MEP1B 1647/4885ALDH1A1 2009/4885KDM4E 864/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MEP1B 1647/4885ALDH1A1 2009/4885KDM4E 864/4885
US-20110251192-A1 AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR PREPARATION METHOD AND THEIR USES CCR5, CCR8, CXCR1 MEP1B 409/4885ALDH1A1 2158/4885KDM4E 2036/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MEP1B 1647/4885ALDH1A1 2009/4885KDM4E 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.